<DOC>
	<DOCNO>NCT00333034</DOCNO>
	<brief_summary>The primary objective ass efficacy safety etanercept 50 mg administer weekly subject psoriasis 12 week .</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy Etanercept 50 mg Once Weekly Subjects With Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Adults great equal 18 year age clinically stable plaque psoriasis involve great equal 10 % body surface minimum Psoriasis Area Severity Index ( PASI ) score 10 screening . Failure respond , contraindication , intolerant least 1 follow systemic phototherapy adequate dose sufficient duration : Methotrexate ( MTX ) , Acitretin , Cyclosporine , Ultraviolet A ( UVA ) , Ultraviolet B ( UVB ) , Psoralen Ultraviolet A ( PUVA ) , Fumarate Previous treatment etanercept , antibody TNF TNF inhibitor . Active guttate , erythrodermic , pustular psoriasis time screen baseline. &amp; # xd ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>